Title: 2017 ACVIM Forum Research Abstract Program Document date: 2017_6_15
ID: ri2w5iby_514
Snippet: There was no significant difference between groups 1 and 2 for duration of therapy, relapse rate or mortality. Thus the hypothesis was accepted. The observations that dogs started on a multi-drug protocol from the outset required a shorter treatment duration, had lower mortality and a lower relapse rate may reflect a type II error due to low group numbers. A prospective study with greater numbers is ongoing to investigate this further. Previous s.....
Document: There was no significant difference between groups 1 and 2 for duration of therapy, relapse rate or mortality. Thus the hypothesis was accepted. The observations that dogs started on a multi-drug protocol from the outset required a shorter treatment duration, had lower mortality and a lower relapse rate may reflect a type II error due to low group numbers. A prospective study with greater numbers is ongoing to investigate this further. Previous studies have demonstrated the ability of liposome-TLR ligand complexes (LTLC) to potently activate innate immune responses in several species, but they have not been fully evaluated for activity in cats. There is currently an unmet need for a broad spectrum immune stimulant for prevention or early treatment of viral and bacterial respiratory tract pathogens in cats. The purpose of the present study was to investigate in vitro responses of cat lymphocytes and monocytes to stimulation by LTLC.
Search related documents:
Co phrase search for related documents- bacterial viral respiratory tract and immune response: 1
- bacterial viral respiratory tract and present study: 1, 2, 3
- bacterial viral respiratory tract and previous study: 1
- bacterial viral respiratory tract and prospective study: 1, 2, 3
- bacterial viral respiratory tract and respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- bacterial viral respiratory tract and significant difference: 1, 2
- bacterial viral respiratory tract and treatment duration: 1
- broad spectrum and cat activity: 1
- broad spectrum and early treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- broad spectrum and group number: 1, 2, 3, 4
- broad spectrum and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- broad spectrum and ligand complex: 1
- broad spectrum and low mortality: 1, 2, 3, 4
- broad spectrum and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69
- broad spectrum and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- broad spectrum and prospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- broad spectrum and respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- broad spectrum and short treatment duration: 1
- broad spectrum and significant difference: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
Co phrase search for related documents, hyperlinks ordered by date